Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.
Douglas E Gladstone, Bo Soo Kim, Kathy Mooney, Andrew H Karaba, Franco R D'Alessio
Author Information
- Douglas E Gladstone: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (D.E.G., K.M.).
- Bo Soo Kim: Johns Hopkins University School of Medicine, Baltimore, Maryland (B.S.K., A.H.K., F.R.D.). ORCID
- Kathy Mooney: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (D.E.G., K.M.).
- Andrew H Karaba: Johns Hopkins University School of Medicine, Baltimore, Maryland (B.S.K., A.H.K., F.R.D.). ORCID
- Franco R D'Alessio: Johns Hopkins University School of Medicine, Baltimore, Maryland (B.S.K., A.H.K., F.R.D.). ORCID
No abstract text available.
- J Clin Invest. 2009 Oct;119(10):2898-913
[PMID: 19770521]
- Cochrane Database Syst Rev. 2020 May 14;5:CD013600
[PMID: 32406927]
- Cell. 2020 May 28;181(5):1036-1045.e9
[PMID: 32416070]
- T32 AI007291/NIAID NIH HHS
Aged
Betacoronavirus
COVID-19
Coronavirus Infections
Humans
Immunotherapy
Male
Middle Aged
Pandemics
Pneumonia, Viral
Respiratory Distress Syndrome
SARS-CoV-2
T-Lymphocytes, Regulatory
